[Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women]
Imaz I, Rubio B, Lopez-Delgado ME, Amate JM, Gomez-Pajuelo P, Gonzalez-Enriquez J
Record ID 32011000304
To assess cost-utility of the most employed pharmacological treatments in Spain for the prevention of bone fractures in osteoporotic post-menopausal Spanish women.
Authors' recommendations: In comparison with calcium and vitamin D, or placebo, treating with alendronate, risedronate, ibandronate, raloxifene or strontium ranelate is not efficient for the prevention of bone fractures in osteoporotic post-menopausal Spanish women when they start treatment before the age of 69. However, if women start treatment at an age of 69 or above, alendronate would be efficient.
Project Status: Completed
URL for project: http://www.isciii.es/htdocs/publicaciones/documentos/63_Osteoporosis_Coste_utilidad_farmacos.pdf
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Cost-Benefit Analysis
- Fractures, Bone
- Osteoporosis, Postmenopausal
Organisation Name: Agencia de Evaluacion de Tecnologias Sanitarias
Contact Address: Jose Luis de Sancho Martin, Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Agencia de Evaluacion de Tecnologias Sanitarias (AETS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.